evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,808 questions · 8,953 findings · 827 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1,891 · 21.1%GRADE not reported 380 · 4.2%Very low 2,100 · 23.5%Low 2,449 · 27.4%Moderate 1,684 · 18.8%High 449 · 5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Aspirin vs vitamin K antagonist (VKA)

Major bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes major bleeding compared with vitamin K antagonist (VKA) (very low certainty).

2 findings from 1 review

Intervention not reported

All‐cause mortality · ≥ 15‐year‐old people with late second stage human African gambiense trypanosomiasis (trypanosomes in blood or nymph node fluid and WBC >…

The intervention showed no clear difference in all‐cause mortality (low certainty).

1 finding from 1 review

Intervention not reported

Relapsec · ≥ 15‐year‐old people with late second stage human African gambiense trypanosomiasis (trypanosomes in blood or nymph node fluid and WBC >…

The intervention probably leads to higher relapsec (moderate certainty).

1 finding from 1 review

Intervention not reported

Serious adverse events · ≥ 15‐year‐old people with late second stage human African gambiense trypanosomiasis (trypanosomes in blood or nymph node fluid and WBC >…

It is very uncertain whether the intervention changes serious adverse events (very low certainty).

1 finding from 1 review

Intervention not reported

Adverse events · ≥ 15‐year‐old people with late second stage human African gambiense trypanosomiasis (trypanosomes in blood or nymph node fluid and WBC >…

The intervention showed no clear difference in adverse events (moderate certainty).

1 finding from 1 review

Zonisamide vs placebo

50% responder rate · people with focal epilepsy

Zonisamide probably leads to higher 50% responder rate (whole treatment period; any dose) compared with placebo (moderate certainty).

1 finding from 1 review

Zonisamide vs placebo

Withdrawal rates ‐ Any dose · people with focal epilepsy

Zonisamide probably leads to higher withdrawal rates (whole treatment period; any dose) compared with placebo (moderate certainty).

1 finding from 1 review

Zonisamide vs placebo

Frequency of adverse effects ‐ dizziness ( · people with focal epilepsy

Zonisamide probably leads to higher adverse effects: dizziness (whole treatment period; any dose) compared with placebo (moderate certainty).

1 finding from 1 review

Zonisamide vs placebo

Adverse effect: fatigue · people with focal epilepsy

Zonisamide probably leads to higher adverse effects: fatigue (whole treatment period; any dose) compared with placebo (moderate certainty).

1 finding from 1 review

Zonisamide vs placebo

Nausea · people with focal epilepsy

Zonisamide probably leads to higher adverse effects: nausea (whole treatment period; any dose) compared with placebo (moderate certainty).

1 finding from 1 review

Zonisamide vs placebo

Somnolence · people with focal epilepsy

Zonisamide probably leads to higher adverse effects: somnolence (whole treatment period; any dose) compared with placebo (moderate certainty).

1 finding from 1 review

EDTA vs placebo

Coronary heart disease mortality – CHD deaths · atherosclerotic cardiovascular disease

It is very uncertain whether EDTA changes coronary heart disease death compared with placebo (very low certainty).

1 finding from 1 review